A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT06012435
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Brief Summary
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy.
This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle.
This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 670
-
Histologically or cytologically confirmed diagnosis of locally advanced, unresectable (Stage IIIB, IIIC), or metastatic Stage IV (M1a, M1b, or M1c) NSCLC American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System (Eighth edition).
-
Participants must have NSCLC with nonsquamous histology
- Tumors with squamous, or predominantly squamous histology are excluded.
- Tumors with small cell elements are excluded.
-
Participants who have NSCLC with known actionable genomic alteration (AGAs) are permitted
-
Participants must have received the following prior therapies and progressed during or relapsed after receiving their most recent prior therapy:
-
Participants with no known AGAs must fulfill 1 of the following conditions:
- Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease and a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy), unless contraindicated.
- Experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant or neoadjuvant setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.
-
Participants with known AGAs must fulfill the following conditions:
- Must have received at least 1 relevant AGA targeted therapy and in the opinion of the investigator, additional AGA targeted therapy is not in the best interest of the participant.
- Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant or neoadjuvant setting
- May have received up to 1 PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
-
-
Measurable disease based on RECIST v1.1
-
Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with adequate baseline hematologic, hepatic, and renal function and measurable disease according to RECIST v1.1
-
Life expectancy of less than (<) 3 months
-
Known allergies/hypersensitivity/intolerance to or contraindication of taxanes, docetaxel, or any excipient contained in the drug formulation of sigvotatug vedotin
-
History of another malignancy within 3 years before Cycle 1 Day 1, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death
-
Participants with any of the following respiratory conditions:
-
Evidence of noninfectious interstitial lung disease (ILD) or pneumonitis that:
- Was previous diagnosed and required systemic steroids, or
- Is currently diagnosed and managed, or
- Is suspected on radiologic imaging at screening
-
Known diffusing capacity of the lung for carbon monoxide (DLCO) < 50%
-
Any Grade greater than or equal to (≥) 3 pulmonary disease unrelated to underlying malignancy
-
-
Pre-existing peripheral neuropathy Grade greater than or equal to (≥) 2
-
Uncontrolled diabetes mellitus
-
Prior therapy:
- Prior treatment with antimicrotubule agents (taxanes, vinca alkaloids, or MMAEs) in the locally advanced, unresectable/refractory, or metastatic setting
- Prior antimicrotubule agent exposure in curative settings (including adjuvant, neoadjuvant, or chemoradiotherapy) is permissible.
- Received more than 1 prior line of cytotoxic chemotherapy in the locally advanced, unresectable/refractory, or metastatic setting
- Prior cytotoxic chemotherapy in curative settings is permissible
- At least 14 days must have elapsed from the last dose of radiotherapy until Cycle 1 Day 1.
- Prior radiation therapy to the lung parenchyma that is >30 Gray (Gy) within 6 months of Cycle 1 Day 1.
- Any systemic anticancer therapy (standard or experimental) within 21 days prior to Cycle 1 Day 1.
-
Active central nervous system (CNS) lesions, including leptomeningeal metastasis, are excluded. Participants with definitively treated brain metastases are eligible in they meet the following criteria:
- Have been clinically stable for at least 4 weeks prior to treatment initiation and baseline scans show no evidence of new or enlarged metastasis
- On a stable dose of less than or equal to (≤) 10mg/day of prednisone or equivalent for a least 2 weeks (if requiring steroid treatment)
- Treatment with corticosteroids greater than (>) 1 month prior to Screening visit
- No evidence of clinical and radiographic disease progression in the CNS for ≥ 21 days after definitive radiotherapy and/or surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental Arm sigvotatug vedotin sigvotatug vedotin monotherapy Control Arm docetaxel Docetaxel monotherapy
- Primary Outcome Measures
Name Time Method Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel) in all participants and in participants whose tumors express high levels of integrin beta-6 (IB6-high) Approximately 5 years The time from date of randomization to date of death due to any cause.
Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR) between the experimental and control arms in all participants and in the IB6-high subgroup Approximately 5 years The time from date of randomization to the first documented disease progression per RECIST v1.1 or to death due to any cause.
- Secondary Outcome Measures
Name Time Method PFS per RECIST v1.1 by investigator assessment Approximately 5 years The time from date of randomization to the first documented disease progression per RECIST v1.1 or to death due to any cause.
Duration of Response (DOR) per RECIST v1.1 by BICR Approximately 5 years The time from the first documented objective response (CR or PR that is subsequently confirmed) to the first documented disease progression per RECIST v1.1 or to death due to any cause.
DOR per RECIST v1.1 by investigator assessment Approximately 5 years The time from the first documented objective response (CR or PR that is subsequently confirmed) to the first documented disease progression per RECIST v1.1 or to death due to any cause.
Number of participants with adverse events (AEs) Through 30 days after the last study intervention; Approximately 5 years An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Confirmed ORR per RECIST v1.1 by investigator assessment Approximately 5 years The proportion of participants with confirmed CR or PR according to RECIST v1.1.
Confirmed Objective Response Rate (ORR) per RECIST v1.1 as assessed by BICR between the experimental and control arms in all participants and in the IB6-high subgroup Approximately 5 years The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1.
Mean score in the global health status/QoL combined score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Approximately 5 years The EORTC QLQ-C30 was developed as a quantitative measure of health-related quality of life (HRQoL). Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Change from baseline in global health status/QoL combined score on the EORTC QLQ-C30 Approximately 5 years The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Mean score in physical functioning scores on the EORTC QLQ-C30 Approximately 5 years The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Change from baseline score in physical functioning scores on the EORTC QLQ-C30 Approximately 5 years The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Mean score in role functioning scores on the EORTC QLQ-C30 Approximately 5 years The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Change from baseline score in role functioning scores on the EORTC QLQ-C30 Approximately 5 years The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Mean scores in the dyspnea, cough, and chest pain scores on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13) Approximately 5 years The EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It incorporates 1 multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Change from baseline in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13 Approximately 5 years The EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It incorporates 1 multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Time to Deterioration (TTD) in the global health status/QoL combined score on the EORTC QLQ-C30 Approximately 5 years TTD is defined as the time from date of randomization to first onset of PRO deterioration with or without subsequent confirmation. The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
TTD in physical functioning scores on the EORTC QLQ-C30 Approximately 5 years TTD is defined as the time from date of randomization to first onset of PRO deterioration with or without subsequent confirmation. The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
TTD in role functioning scores on the EORTC QLQ-C30 Approximately 5 years TTD is defined as the time from date of randomization to first onset of PRO deterioration with or without subsequent confirmation. The EORTC QLQ-C30 was developed as a quantitative measure of HRQoL. Scores range from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
TTD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13 Approximately 5 years TTD is defined as the time from date of randomization to first onset of PRO deterioration with or without subsequent confirmation. The EORTC QLQ-LC13 is a lung-cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire. It incorporates 1 multi-item scale to assess dyspnea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Scores range from 0 to 100. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Trial Locations
- Locations (261)
Inselspital
🇨🇭Bern, Other, Switzerland
Hospital Center De Cornouaille
🇫🇷Quimper Cedex, Other, France
Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou
🇫🇷Rennes, Other, France
Alaska Oncology and Hematology
🇺🇸Anchorage, Alaska, United States
Arizona Oncology Associates
🇺🇸Prescott, Arizona, United States
Cancer and Blood Specialty Clinic
🇺🇸Los Alamitos, California, United States
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
🇺🇸San Francisco, California, United States
Rocky Mountain Cancer Centers - Aurora
🇺🇸Lone Tree, Colorado, United States
Illinois Cancer Care
🇺🇸Niles, Illinois, United States
Cancer Center of Kansas
🇺🇸Wichita, Kansas, United States
Maryland Oncology Hematology, P.A.
🇺🇸Annapolis, Maryland, United States
Southcoast Health
🇺🇸Fall River, Massachusetts, United States
Minnesota Oncology Hematology P.A.
🇺🇸Minneapolis, Minnesota, United States
Allina Health Cancer Institute
🇺🇸Minneapolis, Minnesota, United States
Hattiesburg Clinic Hematology/Oncology
🇺🇸Hattiesburg, Mississippi, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
Summit Medical Group
🇺🇸Florham Park, New Jersey, United States
New Mexico Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Oncology Hematology Care
🇺🇸Cincinnati, Ohio, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic Fairview Hospital
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic, The
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic Hillcrest Hospital
🇺🇸Mayfield Heights, Ohio, United States
Willamette Valley Cancer Institute and Research Center
🇺🇸Eugene, Oregon, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Northwest Cancer Centers, P.C.
🇺🇸Tigard, Oregon, United States
UT Health East Texas Hope Cancer Center
🇺🇸Tyler, Texas, United States
Oncology and Hematology Associates of Southwest Virginia
🇺🇸Blacksburg, Virginia, United States
Vista Oncology Inc PS
🇺🇸Olympia, Washington, United States
Sanatorio Parque
🇦🇷Rosario, Argentina
Algemeen Ziekenhuis Klina
🇧🇪Brasschaat, Other, Belgium
Universitair Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
University Hospital Ghent
🇧🇪Ghent, Other, Belgium
Jessa Ziekenhuis - Campus Virga Jesse
🇧🇪Hasselt, Other, Belgium
CHU de Liege
🇧🇪Liege, Belgium
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
University of Alberta / Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada
McGill University Department of Oncology / McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
BIOCENTER Centro Clinico de Investigacion
🇨🇱Concepción, Other, Chile
Fakultni Nemocnice Olomouc (Fnol) - Onkologicka Klinika
🇨🇿Olomouc, Other, Czechia
Vseobecna fakultni nemocnice v Praze
🇨🇿Prague, Other, Czechia
Centre Hospitalier de Cholet
🇫🇷Cholet, Other, France
Centre Hospitalier Intercommunal Creteil - CHI Creteil
🇫🇷Creteil, Other, France
CHRU de Lille
🇫🇷Lille, Other, France
Hopital Nord Marseille
🇫🇷Marseille, Other, France
Centre de Cancerologie du Grand Montpellier
🇫🇷Montpellier, Other, France
Hopital Cochin
🇫🇷Paris, Other, France
Hopital Bichat-Claude Bernard - APHP
🇫🇷Paris, Other, France
CHU Bordeaux Hopital Haut-Leveque
🇫🇷Pessac, Other, France
Institut de cancerologie Strasbourg Europe
🇫🇷Strasbourg, Other, France
Chits Sainte Musse
🇫🇷Toulon, Other, France
CHU Toulouse - hopital Larrey
🇫🇷Toulouse, Other, France
Institut Gustave Roussy
🇫🇷Villejuif Cedex, Other, France
University Hospital of Besancon
🇫🇷Besancon Cedex, France
Johanniter Krankenhaus Bonn
🇩🇪Bonn, Other, Germany
Klinikum Esslingen GmbH
🇩🇪Esslingen, Other, Germany
Asklepios Klinik Gauting GmbH
🇩🇪Gauting, Other, Germany
LungenClinic Grosshansdorf
🇩🇪Grosshansdorf, Other, Germany
Krankenhaus Martha-Maria Halle-Dölau GmbH
🇩🇪Halle, Other, Germany
Universitatsklinikum Heidelberg
🇩🇪Heidelberg, Other, Germany
Klinikum Kassel GmbH
🇩🇪Kassel, Other, Germany
Alexandra General Hospital of Athens
🇬🇷Athens, Other, Greece
Metropolitan General Hospital
🇬🇷Athens, Other, Greece
University Hospital of Patras
🇬🇷Patras, Other, Greece
National Koranyi Institute of Pulmonology
🇭🇺Budapest, Other, Hungary
Farkasgyepui Tudogyogyintezet
🇭🇺Farkasgyepu, Other, Hungary
Shaare Zedek Medical Center
🇮🇱Jerusalem, Other, Israel
Kaplan Medical Center
🇮🇱Rehovot, Other, Israel
Centro di Riferimento Oncologico di Aviano
🇮🇹Aviano (Pordenone), Other, Italy
Azienda Ospedaliera Spedali Civili di Brescia
🇮🇹Brescia, Other, Italy
Azienda Ospedaliera di Rilievo Nazionale Sant'Anna e San Sebastiano
🇮🇹Caserta, Other, Italy
A.O.U Policlinico G. Rodolico S. Marco
🇮🇹Catania, Other, Italy
Azienda Ospedaliera Universitaria San Martino
🇮🇹Genova, Other, Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori- IRST S.r.l
🇮🇹Meldola, Other, Italy
Ospedale San Raffaele
🇮🇹Milano, Other, Italy
Fondazione IRCCS San Gerardo dei Tintori
🇮🇹Monza, Other, Italy
Azienda Ospedaliero Universitaria di Parma
🇮🇹Parma, Other, Italy
Istituto Nazionale Tumori 'Regina Elena'
🇮🇹Roma, Other, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Other, Italy
A.O.U. - Ospedali Riuniti di Ancona
🇮🇹Torrette, Other, Italy
National Cancer Center Hospital
🇯🇵Chuo-ku, Other, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Koto-ku, Other, Japan
Aichi Cancer Center
🇯🇵Nagoya-shi, Other, Japan
Cryptex Investigacion Clinica S.C.
🇲🇽Distrito Federal, Other, Mexico
Maastricht UMC
🇳🇱Maastricht, Other, Netherlands
Erasmus Medisch Centrum Daniel Den Hoed
🇳🇱Rotterdam, Other, Netherlands
Vestre Viken Health Trust
🇳🇴Drammen, Other, Norway
Oslo University Hospital
🇳🇴Oslo, Other, Norway
St. Olavs Hospital
🇳🇴Trondheim, Other, Norway
Medical University of Gdansk
🇵🇱Gdansk, Other, Poland
Instytut MSF Sp zoo
🇵🇱Lodz, Other, Poland
Institute of Genetics and Immunology GENIM LCC
🇵🇱Lublin, Other, Poland
Med Polonia Sp. z o. o.
🇵🇱Poznan, Other, Poland
Spitalul de Oncologie Monza SRL
🇷🇴Bucuresti, Other, Romania
Institutul Oncologic "Prof. Dr. I. Chiricuta" Cluj-Napoca
🇷🇴Cluj-Napoca, Other, Romania
Medisprof Cancer Center
🇷🇴Cluj-Napoca, Other, Romania
Ovidius Clinical Hospital S.R.L
🇷🇴Constanta, Other, Romania
Centrul de Oncologie Sf Nectarie
🇷🇴Craiova, Other, Romania
Oncocenter-Oncologie Clinica SRL
🇷🇴Timisoara, Other, Romania
Complejo Hospitalario Universitario La Coruna
🇪🇸A Coruna, Other, Spain
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Other, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Other, Spain
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Other, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Other, Spain
Hospital Quiron Salud Malaga
🇪🇸Malaga, Other, Spain
Hospital Universitario Son Espases
🇪🇸Palma de Mallorca, Other, Spain
Fundación Instituto Valenciano de Oncología (FIVO)
🇪🇸Valencia, Other, Spain
Hospital Universitari i Politecnic La Fe de Valencia
🇪🇸Valencia, Other, Spain
Hospital Clinico Universitario Lozano Blesa de Zaragoza
🇪🇸Zaragoza, Other, Spain
Universitatsspital Basel
🇨🇭Basel, Other, Switzerland
Stiftung Kantonsspital Graubunden
🇨🇭Chur, Other, Switzerland
University Hospital Lausanne CHUV
🇨🇭Lausanne, Other, Switzerland
Universitatsspital Zurich
🇨🇭Zurich, Other, Switzerland
Changhua Christian Hospital
🇨🇳Changhua, Other, Taiwan
National Taiwan University Hospital Yunlin Branch
🇨🇳Douliou City, Other, Taiwan
Kaohsiung Medical University Hospital
🇨🇳Kaohsiung, Other, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei City, Other, Taiwan
Barts Health NHS Trust Saint Bartholomews Hospital
🇬🇧London, Other, United Kingdom
Sarah Cannon Research Institute UK
🇬🇧London, Other, United Kingdom
Hospital Provincial del Centenario
🇦🇷Rosario, Argentina
Centro Oncologico de Excelencia
🇦🇷San Juan, Argentina
LKH- Universitat Klinikum Graz
🇦🇹Graz, Austria
Medizinische Universitat Graz - Universitatsklinik fur Radiologie
🇦🇹Graz, Austria
Medizinische Universitat Graz
🇦🇹Graz, Austria
Instituto de Oncologia de Rosario
🇦🇷Rosario, Argentina
Calvary Mater Newcastle
🇦🇺Waratah, New South Wales, Australia
AKH - Medizinische Universitat Wien
🇦🇹Vienna, Austria
Taylor Cancer Research Center
🇺🇸Maumee, Ohio, United States
Sanatorio Allende Cerro
🇦🇷Cordoba, Argentina
Rocky Mountain Cancer Centers LLP
🇺🇸Pueblo, Colorado, United States
Comprehensive Blood and Cancer Center TRIO
🇺🇸Bakersfield, California, United States
St. Joseph Hospital Orange
🇺🇸Orange, California, United States
Sansum Clinic
🇺🇸Solvang, California, United States
Miami Cancer Institute at Baptist Health, Inc.
🇺🇸Miami, Florida, United States
Cancer Care Centers of Brevard, Inc.
🇺🇸Rockledge, Florida, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Saint Luke's Cancer Institute LLC
🇺🇸Kansas City, Missouri, United States
NYU Langone Hospital
🇺🇸Mineola, New York, United States
Alliance Cancer Specialists, PC
🇺🇸Wynnewood, Pennsylvania, United States
Texas Oncology
🇺🇸Wichita Falls, Texas, United States
Alabama Oncology
🇺🇸Birmingham, Alabama, United States
Alaska Oncology and Hematology, LLC
🇺🇸Anchorage, Alaska, United States
Providence St. Jude Medical Center
🇺🇸Fullerton, California, United States
Cancer Blood and Specialty Clinic
🇺🇸Los Alamitos, California, United States
Regulatory Management Only: TRIO-US Central Administration
🇺🇸Los Angeles, California, United States
Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D.
🇺🇸Los Angeles, California, United States
Cancer and Blood Care Specialists
🇺🇸Orange, California, United States
Cancer& Blood Specialty Clinic
🇺🇸Orange, California, United States
UCSF Medical Center - Mission Bay
🇺🇸San Francisco, California, United States
Smilow Cancer Hospital - Trumbull
🇺🇸Trumbull, Connecticut, United States
Smilow Cancer Hospital - Waterbury
🇺🇸Waterbury, Connecticut, United States
Smilow Cancer Hospital - Waterford
🇺🇸Waterford, Connecticut, United States
Cancer Specialists of North Florida
🇺🇸Jacksonville, Florida, United States
Illinois Cancer Specialists
🇺🇸Niles, Illinois, United States
Smilow Cancer Hospital - Derby
🇺🇸Derby, Connecticut, United States
Smilow Cancer Hospital - Fairfield
🇺🇸Fairfield, Connecticut, United States
Smilow Cancer Hospital - Glastonbury
🇺🇸Glastonbury, Connecticut, United States
Smilow Cancer Hospital - Greenwich
🇺🇸Greenwich, Connecticut, United States
Smilow Cancer Hospital - Guilford
🇺🇸Guilford, Connecticut, United States
Smilow Cancer Hospital at St. Francis
🇺🇸Hartford, Connecticut, United States
Smilow Cancer Hospital - Yale New Haven Health
🇺🇸New Haven, Connecticut, United States
Yale - New Haven Hospital - Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Smilow Cancer Hospital - North Haven
🇺🇸North Haven, Connecticut, United States
Smilow Cancer Hospital - Torrington
🇺🇸Torrington, Connecticut, United States
Maryland Oncology Hematology P.A.
🇺🇸Columbia, Maryland, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Southcoast Centers for Cancer Care
🇺🇸Fall River, Massachusetts, United States
Minnesota Oncology Hematology, P.A
🇺🇸Woodbury, Minnesota, United States
Allina Health Cancer Institute - Mercy Hospital
🇺🇸Coon Rapids, Minnesota, United States
M Health Fairview Cancer Clinic-Edina
🇺🇸Edina, Minnesota, United States
M Health Fairview St. John's Hospital
🇺🇸Maplewood, Minnesota, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital
🇺🇸Minneapolis, Minnesota, United States
Hennepin County Medical Center
🇺🇸Minneapolis, Minnesota, United States
North Memorial Health Cancer Center
🇺🇸Robbinsdale, Minnesota, United States
Park Nicollet Frauenshuh Cancer Center
🇺🇸Saint Louis Park, Minnesota, United States
Regions Hospital
🇺🇸Saint Paul, Minnesota, United States
Allina Health Cancer Institute - United Hospital
🇺🇸Saint Paul, Minnesota, United States
Hattiesburg Clinic Hematology/Oncology.
🇺🇸Hattiesburg, Mississippi, United States
University of Nebraska Medical Center.
🇺🇸Omaha, Nebraska, United States
University of New Mexico Comprehensive Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
🇺🇸Mineola, New York, United States
Laura & Isaac Perlmutter Cancer Center - NYU ACC
🇺🇸New York, New York, United States
Laura& Isaac Perlmutter Cancer Center at NYU Langone Health
🇺🇸New York, New York, United States
NYU Langone Medical Center
🇺🇸New York, New York, United States
University Hospitals Seidman Cancer Center at UH Avon Health Center
🇺🇸Avon, Ohio, United States
Oncology Hematology Care Clinical Trials, LLC
🇺🇸Fairfield, Ohio, United States
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
🇺🇸Cleveland, Ohio, United States
Fairview Hospital Moll Pavilion - Cleveland Clinic Cancer Center
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Hillcrest Hospital - Cleveland Clinic Cancer Center
🇺🇸Mayfield Heights, Ohio, United States
University Hospitals Seidman Cancer Center at UH Mentor Health Center
🇺🇸Mentor, Ohio, United States
UH Minoff Health Center at Chagrin Highlands
🇺🇸Orange Village, Ohio, United States
Oregon Health and Science University - CHO Beaverton
🇺🇸Beaverton, Oregon, United States
Oncology Associates of Oregon, P.C.
🇺🇸Eugene, Oregon, United States
Oregon Health and Science University - CHO Gresham
🇺🇸Gresham, Oregon, United States
Oregon Health and Science University - CHO Northwest
🇺🇸Portland, Oregon, United States
Oregon Health and Science University - CHO East Portland
🇺🇸Portland, Oregon, United States
Froedtert Hospital/Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Oregon Health and Science University (CHH1)
🇺🇸Portland, Oregon, United States
Oregon Health and Science University (CHH2)
🇺🇸Portland, Oregon, United States
Oregon Health and Science University - CHO Tualatin
🇺🇸Tualatin, Oregon, United States
University of Texas Southwestern Medical Center - Simmons Cancer Center
🇺🇸Dallas, Texas, United States
University Of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center - Redbird
🇺🇸Dallas, Texas, United States
Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital
🇺🇸Dallas, Texas, United States
Northwest Cancer Specialists, P.C.
🇺🇸Vancouver, Washington, United States
University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital
🇺🇸Dallas, Texas, United States
UT Southwestern - Simmons Cancer Center - Fort Worth
🇺🇸Fort Worth, Texas, United States
CEMAIC - Centro Medico Privado
🇦🇷Cordoba, Argentina
US Oncology Investigational Product Center (IPC)
🇺🇸Irving, Texas, United States
Texas Oncology - Gulf Coast
🇺🇸Pearland, Texas, United States
UT Southwestern - Simmons Cancer Center - Richardson/Plano
🇺🇸Richardson, Texas, United States
The University of Texas Health Science Center at Tyler on behalf of UT
🇺🇸Tyler, Texas, United States
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
🇺🇸Salem, Virginia, United States
Oncology & Hematology Associates of Southwest Virginia, INC.
🇺🇸Wytheville, Virginia, United States
Northwest Medical Specialties, PPLC
🇺🇸Tacoma, Washington, United States
American Oncology Network Vista Oncology Division-West office
🇺🇸Olympia, Washington, United States
American Oncology Network Vista Oncology Division
🇺🇸Olympia, Washington, United States
Instituto de Investigaciones Clinicas de Mar del Plata
🇦🇷Mar del Plata, Argentina
Border Medical Oncology
🇦🇺Albury, New South Wales, Australia
Ramsay Health Care Australia Pty Ltd
🇦🇺Albury, New South Wales, Australia
GenesisCare Kingswood
🇦🇺Kingswood, New South Wales, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
St. John of God Hospital Murdoch
🇦🇺Murdoch, Other, Australia
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Algemeen Ziekenhuis klina
🇧🇪Brasschaat, Belgium
Universitair Ziekenhuis Gent
🇧🇪Ghent, Belgium
Jessa Ziekenhuis VZW
🇧🇪Hasselt, Belgium
Fundacao Doutor Amaral Carvalho
🇧🇷Jaú, SAO Paulo, Brazil
William Osler Health Sciences
🇨🇦Brampton, Ontario, Canada
St John of God Hospital Murdoch
🇦🇺Murdoch, Western Australia, Australia
Frankston Hospital
🇦🇺Frankston, Australia
Medizinische Universitat Graz - Diagnostik- & Forschungsinstitut fur Pathologie
🇦🇹Graz, Austria
Medizinische Universitat Graz - Klinische Abteilung fur Nuklearmedizin
🇦🇹Graz, Austria
Riedl-Prayer-Drahanowsky-Barton Radiologiegruppenpraxis OG (RPDB)- Imagingpraterstern
🇦🇹Wien, Austria
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
🇧🇷Santo Andre, SAO Paulo, Brazil
Centro Paulista de Oncologia S A
🇧🇷Vila Olímpia, SAO Paulo, Brazil
Hospital de Cancer de Barretos - Fundacao Pio XII
🇧🇷Barretos, Brazil
Centro Regional Integrado de Oncologia.
🇧🇷Fortaleza, Brazil
Oncosite - Centro de Pesquisa Clinica e Oncologia
🇧🇷Ijui, Brazil
Hospital Mãe de Deus
🇧🇷Porto Alegre, Brazil
Sao Lucas Hospital of PUCRS
🇧🇷Porto Alegre, Brazil
NOB - Nucleo de Oncologia da Bahia
🇧🇷Salvador, Brazil
Arthur J.E. Child Comprehensive Cancer Centre
🇨🇦Calgary, Alberta, Canada
Peel Memorial Hospital
🇨🇦Brampton, Ontario, Canada
Providence Medical Foundation
🇺🇸Orange, California, United States
Etobicoke General Hospital
🇨🇦Etobicoke, Ontario, Canada
CISSS de la Monteregie-Centre
🇨🇦Greenfield Park, Quebec, Canada
CeCim Biocinetic
🇨🇱Santiago, Region Metropolitana, Chile
CDIEM - Centro de Investigación y Especialidades Medicas
🇨🇱Providencia, Santiago, Chile
Centro de Investigaciones Clinicas Viña del Mar Ltda.
🇨🇱Vina del Mar, Valparaíso, Chile
BIOCENTER Centro Clínico de Investigación
🇨🇱Concepción, Chile
Centro de Investigacion Clinica Bradford Hill
🇨🇱Santiago, Chile
The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
McGill University Department of Oncology/McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
Fujian provincial Cancer Hospital
🇨🇳Fuzhou, Fujian, China
The First People's Hospital of Foshan
🇨🇳Foshan, Guangdong, China